Does Wegovy help with belly fat, and how does it work?

Does Wegovy specifically target belly fat, or does it reduce fat all over?

A question our prescribers hear most weeks: "Will it go for the belly first?" The honest answer is that semaglutide doesn't pick its spots. It works by reducing your overall calorie intake (by dampening appetite signals and slowing gastric emptying) which leads to a sustained energy deficit. Your body then draws on its fat stores across the whole body, not from one location on command.

That said, visceral fat (the deep abdominal tissue wrapped around the liver, pancreas and intestines) tends to be metabolically active and is often released more readily in response to sustained calorie restriction than subcutaneous fat, which sits just under the skin. Several imaging sub-studies within large semaglutide trials recorded meaningful reductions in visceral fat area alongside total body-weight loss. The STEP 1 trial published in the New England Journal of Medicine (1,961 adults without diabetes, 68 weeks) found around 15% average weight reduction at 2.4 mg. Participants also saw improvements in waist circumference, a proxy measure for abdominal fat burden.

So while the medicine won't dissolve belly fat in isolation, sustained weight loss of 10–15% of body weight does tend to have a meaningful effect on the waist. If you want a deeper look at the research, our page on how Wegovy relates to belly fat pulls together the clinical evidence in one place. Expecting a flat stomach in the first few weeks isn't realistic; expecting a noticeably smaller waist after several months of treatment, alongside a reduced-calorie diet and more activity, is supported by the evidence.

How does semaglutide actually reduce fat stores?

Wegovy contains semaglutide, a GLP-1 receptor agonist. GLP-1 is a hormone released naturally in the gut after eating; it signals fullness to the brain, slows how quickly food leaves the stomach, and influences insulin release. The drug mimics this signal at a much higher level than the body produces on its own, which is why people on it often report eating noticeably less without feeling deprived.

Reduced appetite leads to fewer calories consumed. Fewer calories consumed, sustained over months, produces a genuine energy deficit. The body uses stored fat to fill that gap. The GLP-1 pathway also has some direct effects on fat-cell metabolism that researchers are still characterising, but the dominant mechanism is behavioural: you eat less, consistently, and weight comes off.

Wegovy is a GLP-1 receptor agonist, whereas semaglutide's profile covers the wider clinical picture of this drug class. For those curious about how the mechanism compares across medicines, our overview of weight-loss treatments sets out the options licensed in the UK.

One practical point: the dose escalates over several months, starting at 0.25 mg and working up to 2.4 mg maintenance. The lower early doses are about settling your system rather than producing maximum weight loss, so the most significant changes in body composition tend to come later in treatment.

Who qualifies for Wegovy, and does the belly-fat indication affect eligibility?

Wegovy's UK licence covers adults with a BMI of 30 or above, or 27–29.9 where at least one weight-related health condition is present. Abdominal obesity doesn't appear as a standalone criterion, eligibility is based on BMI and overall clinical picture. Lower BMI thresholds apply for people from some ethnic backgrounds where cardiovascular and metabolic risk accumulates at lower BMIs, which NICE's recommendation for semaglutide (TA875) addresses in detail.

On the NHS, Wegovy is currently accessed through specialist weight management services under strict criteria, and waiting lists are long. Private prescribing through a regulated online pharmacy is the alternative for people who meet the licensed criteria but don't want to wait. If you're curious about what getting started privately looks like, the guide to where Wegovy is available in the UK covers the verification steps worth taking before choosing any provider.

A prescriber considers more than just your BMI. Medical history, current medicines, contraindications and your goals all feed into the decision. Belly fat as a concern is a completely valid reason to explore treatment, and our guide on whether Wegovy helps lose belly fat walks through what the evidence realistically supports. Just know the approval process evaluates the whole clinical picture, not the location of your fat.

What else helps Wegovy work better for abdominal fat loss?

The licence for Wegovy specifies use "alongside a reduced-calorie diet and increased physical activity", and that's not small print. People who pair the medicine with genuinely sustainable lifestyle changes lose more weight and retain more of that loss over time. For abdominal fat specifically, some evidence points to resistance exercise as particularly useful: building muscle mass helps maintain metabolic rate as weight falls, and tends to shift body composition in ways that cardio alone doesn't.

Protein intake matters more on GLP-1 medicines than off them. Appetite suppression can sometimes lead people to eat too little protein, which risks losing muscle rather than fat. Keeping protein adequate (which a prescriber or dietitian can guide you on) helps ensure that the weight coming off is predominantly fat rather than lean tissue.

The NHS medicines page for semaglutide gives a good grounding in how the drug should be used in practice. For a broader look at what to expect from treatment, our Wegovy overview covers the full picture, from starting the treatment through to maintenance.

Ready to find out whether you're clinically suitable? If you'd like to begin sooner rather than later, our page on finding Wegovy nearby can help you locate a regulated provider close to you. Start your free consultation with our prescribers, reviewed the same day, in plain packaging the next working day if approved.